BofA Upgrades Moderna Following Cancer Vaccine Breakthrough-Driven Rally

Bank of America has upgraded Moderna's stock rating after the company experienced a 177% rally, fueled by a breakthrough in its cancer vaccine research. The upgrade reflects increased confidence in Moderna's pipeline and future growth prospects within the biotechnology sector.

BofA Upgrades Moderna Following Cancer Vaccine Breakthrough-Driven Rally

Related Articles

Synopsys Reports Strong Q3 FY2026 Results, Revenue Reaches $2.477 Billion

Dow Slides on Inflation Data; Nvidia Declines Ahead of Earnings, Micron Rises

Vanguard Acquires Altruist for $4 Billion, Boosting Advisory Services

American Airlines Plane Experiences Tire Blowout at O'Hare